(February 2, 2017, 1:54 PM EST) -- WASHINGTON, D.C. — A federal judicial panel on Feb. 2 denied a motion to centralize 39 federal lawsuits alleging kidney injury from proton pump inhibitor (PPI) drugs because they involve four groups of competing manufacturers and because discovery will be “defendant-specific” (In Re: Proton Pump Inhibitor Products Liability Litigation, MDL Docket No. 2757, JPMDL)....